Literature DB >> 3082958

Echocardiographic abnormalities and disease severity in Fabry's disease.

M E Goldman, R Cantor, M F Schwartz, M Baker, R J Desnick.   

Abstract

Fabry's disease is an X-linked recessive genetic deficiency of the enzyme alpha-galactosidase A, which leads to the pathologic deposition of neutral glycosphingolipids in lysosomes of the vascular endothelium of the heart, brain and kidney. The disease is progressive in hemizygous male patients, with increasing involvement of the major organs leading to death. Because cardiac involvement is a constant feature, echocardiograms were performed on 35 patients with Fabry's disease, 23 hemizygotes (aged 28.6 +/- 14 years) and 12 heterozygotes (aged 31.6 +/- 6 years), to determine whether cardiac involvement could be detected noninvasively. The results demonstrated that hemizygous male patients had a greater aortic root diameter, thicker interventricular septum and greater ventricular mass than did heterozygous female patients. Left ventricular mass per square meter of body surface area correlated well with clinical disease severity (r = 0.68, p less than 0.05), suggesting progressive glycosphingolipid deposition. Older heterozygotes (greater than 25 years old) had more severe evidence of cardiac disease than did younger male patients. Although mitral valve prolapse was identified in 12 (54%) of 23 male hemizygotes and in 7 (58%) of 12 female heterozygotes its presence did not correlate with clinical disease severity or other echocardiographic variables. Therefore, echocardiographic evidence of Fabry's disease appears to correlate with age-related disease severity and may be a useful noninvasive marker to follow disease progression and possible regression when appropriate therapy becomes available.

Entities:  

Mesh:

Year:  1986        PMID: 3082958     DOI: 10.1016/s0735-1097(86)80238-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Cardiac manifestations in Fabry disease.

Authors:  A Linhart; J C Lubanda; T Palecek; J Bultas; D Karetová; J Ledvinová; M Elleder; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 3.  Anderson-Fabry disease.

Authors:  S H Morgan; M A Crawfurd
Journal:  BMJ       Date:  1988-10-08

4.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

Review 5.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

6.  Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.

Authors:  Dominique P Germain; Paul Avan; Augustin Chassaing; Pierre Bonfils
Journal:  BMC Med Genet       Date:  2002-10-11       Impact factor: 2.103

Review 7.  Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review.

Authors:  Aidonis Rammos; Vasileios Meladinis; Georgios Vovas; Dimitrios Patsouras
Journal:  Radiol Res Pract       Date:  2017-11-15

Review 8.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

9.  Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

Authors:  J W Koskenvuo; J J Hartiala; P Nuutila; R Kalliokoski; J S Viikari; E Engblom; M Penttinen; J Knuuti; I Mononen; I M Kantola
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.750

Review 10.  Striving towards the ideal cardiac functional assessment strategy: the contribution of tissue Doppler, strain and strain rate imaging.

Authors:  J C Mooman-Smook; P A Brink
Journal:  Cardiovasc J Afr       Date:  2007 Nov-Dec       Impact factor: 1.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.